TW201410676A - 芳基內醯胺激酶抑制劑 - Google Patents

芳基內醯胺激酶抑制劑 Download PDF

Info

Publication number
TW201410676A
TW201410676A TW102127296A TW102127296A TW201410676A TW 201410676 A TW201410676 A TW 201410676A TW 102127296 A TW102127296 A TW 102127296A TW 102127296 A TW102127296 A TW 102127296A TW 201410676 A TW201410676 A TW 201410676A
Authority
TW
Taiwan
Prior art keywords
amino
naphthyridin
group
oxy
alkyl
Prior art date
Application number
TW102127296A
Other languages
English (en)
Chinese (zh)
Inventor
菲佛卡南達M 福魯赫拉
潘森梁
羅庫瑪 雷賈曼恩
瑟斯希爾 傑森安德 那拉
瑪希斯瓦倫 希法沙賓 卡拉索魯胡
塔朗 庫瑪 梅修
強納森L 迪塔
卡洛琳 戴安 德茲爾巴
瓊安J 布朗森
約翰E 馬可
Original Assignee
必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 必治妥美雅史谷比公司 filed Critical 必治妥美雅史谷比公司
Publication of TW201410676A publication Critical patent/TW201410676A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW102127296A 2012-07-31 2013-07-30 芳基內醯胺激酶抑制劑 TW201410676A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261677856P 2012-07-31 2012-07-31
US13/946,344 US8901305B2 (en) 2012-07-31 2013-07-19 Aryl lactam kinase inhibitors

Publications (1)

Publication Number Publication Date
TW201410676A true TW201410676A (zh) 2014-03-16

Family

ID=50026068

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102127296A TW201410676A (zh) 2012-07-31 2013-07-30 芳基內醯胺激酶抑制劑

Country Status (12)

Country Link
US (1) US8901305B2 (OSRAM)
EP (1) EP2880032B1 (OSRAM)
JP (1) JP2015528018A (OSRAM)
CN (1) CN104507941A (OSRAM)
AR (1) AR093758A1 (OSRAM)
BR (1) BR112015001890A2 (OSRAM)
CA (1) CA2880523A1 (OSRAM)
EA (1) EA201590268A1 (OSRAM)
ES (1) ES2602965T3 (OSRAM)
MX (1) MX2015000980A (OSRAM)
TW (1) TW201410676A (OSRAM)
WO (1) WO2014022167A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708337B2 (en) 2013-02-22 2017-07-18 Bristol-Myers Squibb Company Aryl amide-based kinase inhibitors
CN105517993B (zh) 2013-07-08 2018-07-13 百时美施贵宝公司 芳基酰胺激酶抑制剂
EP3054955B1 (en) 2013-10-11 2018-05-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EA028587B1 (ru) * 2014-01-29 2017-12-29 Бристол-Майерс Сквибб Компани Ариллактамные ингибиторы киназы
PT3126351T (pt) * 2014-04-02 2018-12-04 Bristol Myers Squibb Co Inibidores de biaril quinase
US10174044B2 (en) * 2015-04-10 2019-01-08 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
US10544120B2 (en) 2015-10-01 2020-01-28 Bristol-Myers Squibb Company Biaryl kinase inhibitors
WO2017059080A1 (en) * 2015-10-01 2017-04-06 Bristol-Myers Squibb Company Biaryl kinase inhibitors
WO2021026349A1 (en) * 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
CN114853664B (zh) * 2022-06-02 2023-09-29 河南大学 一种钯催化条件下合成α,β-不饱和杂环己基酮类化合物的方法
CN116102542A (zh) * 2023-02-15 2023-05-12 如东众意化工有限公司 环丙唑醇精制母液中环丙唑醇的回收方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ATE234270T1 (de) 1992-12-02 2003-03-15 Pfizer Cathecoldiether als selektive pde iv hemmungsmittel
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
EP1495009B1 (en) 2002-04-05 2008-03-12 Boehringer Ingelheim Pharmaceuticals Inc. Cyanamides useful as reversible inhibitors of cysteine proteases
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2004072018A1 (ja) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited アミン誘導体
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
JP2007523109A (ja) * 2004-02-18 2007-08-16 エフ.ホフマン−ラ ロシュ アーゲー 複素環式Gaba−Aサブタイプ選択的レセプターモジュレーター
EP1773780A4 (en) 2004-06-24 2008-01-09 Incyte Corp AMIDO COMPOUNDS AND USES THEREOF AS PHARMACEUTICAL PRODUCTS
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
JP2009519279A (ja) * 2005-12-15 2009-05-14 エフ.ホフマン−ラ ロシュ アーゲー 三員環ラクタム誘導体、それらの製造方法、及び医薬剤としての使用
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
AU2007223342A1 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
PL2674428T3 (pl) 2006-04-07 2017-01-31 Vertex Pharmaceuticals Incorporated Modulatory transporterów z kasetą wiążącą ATP
WO2008022154A2 (en) 2006-08-14 2008-02-21 Wyeth Methods of identifying agents for treating neurological disorders
AU2007336933A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
AU2010249015A1 (en) * 2009-05-15 2011-11-24 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
WO2011123493A1 (en) * 2010-03-31 2011-10-06 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
HK1199814A1 (en) 2012-03-09 2015-07-24 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
MX381849B (es) 2012-03-09 2025-03-13 Lexicon Pharmaceuticals Inc Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.
EP2822559B1 (en) 2012-03-09 2018-05-02 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors

Also Published As

Publication number Publication date
EP2880032A1 (en) 2015-06-10
US20140038999A1 (en) 2014-02-06
JP2015528018A (ja) 2015-09-24
ES2602965T3 (es) 2017-02-23
AR093758A1 (es) 2015-06-24
US8901305B2 (en) 2014-12-02
MX2015000980A (es) 2015-04-10
CN104507941A (zh) 2015-04-08
BR112015001890A2 (pt) 2017-07-04
CA2880523A1 (en) 2014-02-06
EA201590268A1 (ru) 2015-05-29
WO2014022167A1 (en) 2014-02-06
EP2880032B1 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
TW201410676A (zh) 芳基內醯胺激酶抑制劑
CN106458994B (zh) 联芳激酶抑制剂
CN108290843B (zh) 联芳基激酶抑制剂
TWI702218B (zh) 選擇性經取代之喹啉化合物
CN108368084B (zh) 联芳基激酶抑制剂
CN110156772B (zh) 一种杂环化合物、其应用及含其的药物组合物
CN102548557B (zh) 用于降低β-淀粉状蛋白生成的化合物
CN105939997B (zh) 作为dlk抑制剂的吡唑衍生物及其用途
TWI639602B (zh) 三環旋轉酶抑制劑
TWI480282B (zh) 稠合雜環衍生物及其用途
CN108689942B (zh) 含氮双环化合物及其制备方法和用途
CN113227068A (zh) Glp-1r激动剂及其用途
CN105517993B (zh) 芳基酰胺激酶抑制剂
CN106132414A (zh) 芳基内酰胺激酶抑制剂
WO2024083258A1 (zh) Kras g12d降解剂及其制备方法和应用
TW201414737A (zh) 作爲激酶抑制劑之咪唑并三□甲腈
TW201434825A (zh) 3-取代吡唑及其用途
TW201341385A (zh) 咪唑[1,2-b]噠嗪基化合物、包含其之組成物及其使用方法
JP2023501399A (ja) ヘテロ環式rip1阻害化合物
CN107108552A (zh) 杂环激酶抑制剂
CN111032641A (zh) 经取代的5-氰基吲哚化合物及其用途
CN110461842A (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
CN117881683A (zh) PI3Kα抑制剂及其使用方法
TW201609698A (zh) 三環磺醯胺衍生物
CN117355523A (zh) 血浆激肽释放酶的多环抑制剂